November 3, 2011
It's been a busy earnings week, and five North Carolina firms all reported losses.
September 8, 2011
A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.
Updated August 16, 2011
The Chapel Hill-based pharmaceutical firm looks to boost its own pipeline of products.
August 8, 2011
Pozen had sued the Par, Alphapharm and Dr. Reddy's claiming that those generic product infringe on its three migraine drug patents. The litigation was consolidated into one suit that was tried last October.
July 22, 2011
The Chapel Hill-based pharmaceutical firm is seeking advice about how to revolutionize drug industry marketing and development.
April 15, 2011
The court order bars Par Pharmaceutical from producing a version of Pozen's Treximet, which is sold by GlaxoSmithKline.
March 9, 2011
The Chapel Hill-based drug development firm reports a positive fourth quarter and full year financials.
Updated February 25, 2011
Shares in Pozen took a hit Thursday after the Chapel Hill-based company failed to win an extension of exclusivity for pediatric use of its migraine drug Treximet.
Updated November 3, 2010
The Chapel Hill firm receives the funds under law that focuses on providing incentives for new drugs.
May 26, 2010
The Chapel Hill-based pharmaceutical firm could receive another $25 million if the pain reliever developed in partnership with AstraZeneca is approved for sale in Europe.
Updated May 3, 2010
Pozen and its partner AstraZeneca can sell Vimovo, which combines a painkiller with the main ingredient in the ulcer medicine Nexium.